COVID-19 and IBD Webinar 01 May 2020
Rules of engagement • Please remember to mute your phone or computer when you are not speaking • If you want to make a comment or ask a question, please enter a notification in the chat box • We need to stay on time • Please try to hold comments and questions until the end of each presentation • We’ll likely need to cut off comments and questions to keep moving
Agenda 01 May 2020 8:00am – 8:05am Welcome Maria Abreu 8:05am - 8:15am IOIBD Gives project Gil Kaplan 08:15am-08:25am Stride-II project update Dan Turner 8:25am - 8:30am Update Task Force ‘Research’ Dermot McGovern 8:30am - 8:35am Update Task Force ‘Telehealth’ Uma Mahadevan 8:35am – 8:40am Update Task Force ‘Recommendations’ Corey Siegel 8:40 am – 8:45am Update publications Corey Siegel, Feza Remzi 8:45am - 08:50am JCC online publication, together with ECCO Maria Abreu, Laurent Peyrin-Biroulet 8:50am - 08:55am AGA University, FDA Letter Maria Abreu 08:55am-09:00am Any other business + Closing Maria Abreu
IO IOIB IBD GIV IVES PROJECT Gil il Kaplan
IO IOIBD GIV IVES: Glo lobal l IB IBD Vis isualization of Epid idemiology Studies (GIV IVES) • Funded by a pilot grant by IOIBD: Globalization Cluster • Collaboration: Siew Ng, Richard Geary, 1. Systematic review of population-based studies of burden of IBD • Incidence & Prevalence • Hospitalization, Surgery • Analytics: Data visualizations, pooling, temporal trends, forecasting 2. Interactive atlas for users to share maps and graphs on the epidemiology of IBD using ArcGIS 3. Updating data synthesis and review on a regular basis • Published manuscripts periodically (static map – snapshot in time) • Data updated continuously (dynamic map – real-time data)
https://ucalgary.maps.arcgis.com/apps/MapSeries/index.h tml?appid=93e520cd04624e128f7acbb238f7ef87
Governance and Future Studies Governance • Gil Kaplan, Siew Ng, Richard Gearry • Country +/- Regional Custodian • Verification, Updating, identify and oversee affiliate custodian IOIBD Members • Country Custodian • Non-members – verification, updating IOIBD • Carry out research in gap countries Affiliate
Next Step: Data Verification (Excel Sheet and PDF Folder)
STRIDE II II update Dan Turner
STRIDE-II: a position paper from IOIBD on targets of IBD Treatment Powered by
Results of f th the 1st voting round
Results of the second voting round 100 90 80 70 60 50 40 30 20 10 0 Clinical remission is Measures to Histology is not a TH is not a target Disability and QOL Fatiue is a target Depression and Agree with the a target explore MH target are targets anxiety are targets figure
Updates Taskforce groups
IOIBD COVID-19 RESEARCH TASKFORCE DERMOT, GIL, IRIS, SEVERINE, ARIE, VINEET, BRITTA, FLAVIO, ZHIHUA, BALFOUR, DAVID, WALTER, MATTHIEU
IOIBD COVID-19 RESEARCH TASKFORCE DERMOT, GIL, IRIS, SEVERINE, ARIE, VINEET, BRITTA, FLAVIO, ZHIHUA, BALFOUR, DAVID, WALTER, MATTHIEU
Carriage of virus in gut epithelium / stool and impact on endoscopy processing stool • samples etc. What about the risk of infection of colonoscopy? Re-initiating IBD treatment in IBD patients resolving COVID-19 • ADDITIONAL • What explains the very low incidence of COVID-19 in children? Is it subclinical infection or do they not acquire SARS-COV2? Could assessment of stool and NP cultures for SUGGESTIONS FROM SARS-COV2 (and serology) of children help answer this? IOIBD – THANK YOU! Is nontoxic U-V lighting in endoscopy and other procedure suites something to think • about? When to restart medications following COVID-19 • DERMOT, GIL, IRIS, SEVERINE, ARIE, VINEET, BRITTA, FLAVIO, ZHIHUA, • Are patients receiving immunosuppressant medications and who work in healthcare at greater risk of developing COVID-19 than healthcare workers without IBD or with IBD BALFOUR, DAVID, WALTER, on no immunosuppressant medications. MATTHIEU • How safe are mesalamine medications in terms of COVID-19 outcomes • Which dose of prednisone/solone is a significant risk?
Next Steps IOIBD COVID-19 • Manuscript RESEARCH TASKFORCE • Designed around table and text referring to table • Appendix – ‘consensus data collection form’ • RAND-type data collection from IOIBD etc on DERMOT, GIL, IRIS, priorities SEVERINE, ARIE, • Research Proposal Structures/Protocols VINEET, BRITTA, FLAVIO, • Serology registry/biobank ZHIHUA, BALFOUR, DAVID, • Gut Epithelium and virus WALTER, MATTHIEU • Stool • ‘Speed dating’ for COVID -19 IBD research
Telehealth Uma Mahadevan, Charlie Lees, Miguel Regueiro, Ailsa Hart, Pia Munkholm
Deliverables • Telehealth paper for JCC with best practices table for website • Completed. With publications committee • Telehealth survey • 754 respondents in 54 countries • Commentary for Gastroenterology • In process
United Kingdom 90 United States 83 Italy 78 IOIBD telemedicine Brazil 43 Israel 36 India 28 New Zealand 28 Denmark 25 and IBD survey Romania 25 Canada 23 Spain 23 Algeria; 0; China 22 China; 22; Australia; 18; 2% Belgium; 15; 2% Austria; 1; 0% 0% Greece 21 3% Argentina; 3; 0% Ireland 19 Canada; 23; 3% Australia 18 Kuwait 17 Costa Rica; Bulgaria; 1; 0% Brazil; Saudi Arabia 17 United States; 83; 2; 0% 43; 6% Lebanon 16 11% Chile; 1; 0% Belgium 15 Colombia; Croatia; 3; 0% Sweden 14 6; 1% Norway 12 Denmark; 25; 3% Hong Kong 8 Japan 7 Czech Republic; 3; 0% Egypt; 5; Colombia 6 United Arab 1% Estoni Germany 6 France; 3; 0% Emirates; 4; 1% United Kingdom; 90; 12% a; 1; Turkey; 3; 0% South Africa 6 Faroe Islands; 1; 0% 0% Egypt 5 Switzerland; 2; 0% Germany; 6; 1% Korea, Republic of 5 Netherlands 5 Sweden; 14; 2% Greece; 21; 3% United Arab Emirates 4 Argentina 3 Hong Kong; 8; 1% Spain; 23; 3% Croatia 3 Czech Republic 3 South Africa; 6; 1% India; 28; 4% Hungary; 2; 0% France 3 Malaysia 3 San Marino; 1; 0% Turkey 3 Slovenia; 1; 0% Ireland; 19; 3% Romania; 25; 3% Costa Rica 2 Hungary 2 Poland; 1; 0% Saudi Arabia; 17; 2% Portugal; 2; 0% Portugal 2 Israel; 36; 5% Italy; 78; 10% Niger; 1; 0% Switzerland 2 Norway; 12; 2% Austria 1 Moldova, Nigeria; 1; 0% Bulgaria 1 New Zealand; 28; 4% Lithuania; 1; 0% Republic of; Korea, Republic of; 5; 1% Chile 1 1; 0% Malta; 1; 0% Netherlands; 5; 1% Lebanon; 16; 2% Estonia 1 Kuwait; 17; 2% Malaysia; 3; 0% Japan; 7; 1% Faroe Islands 1 N=754 Lithuania 1 Malta 1 82.4% are gastroenterologists Moldova, Republic of 1 Niger 1 10.1% are IBD specialist nurses Nigeria 1 Poland 1 4.1% are surgeons San Marino 1 Slovenia 1
Prior to the COVID-19 pandemic almost all IBD clinic was performed face-to-face with virtually zero video consult
During the COVID-19 pandemic face-to-face visits have almost completely disappeared, replace by either phone (the majority) or video consultation
After COVID-19, things will not return to normal. Many face-to-face visits will be replaced by phone or video consultation.
Update Publications
Update Communication
IO IOIB IBD websit ite facelif lift - sn sneak previe iew - also check the attached pdf! • Please send us cool IBD images related to Endoscopy, Research etc. to be used on our website • Check the current site: www.ioibd.org • Also check the current web statistics with major increase since last month: https://www.ioibd.org/webstat/
•Told Larry Egan we would have articles by May 8 th , 2020 •Review of taskforce articles by publications committee •We would like volunteers for reviewing these JCC and AGA to help Corey and co University •Slides of your task force output (basically slide version of your papers) as soon as possible to have AGA fix and put on website •Interest in recording audio and/or video for your slides
Suggested titles for Taskforce output JCC Supplement • Management of outpatient IBD during COVID — Corey Siegel • What to do with the hospitalized IBD pt during COVID — David Rubin • Dialing on telemedicine in IBD — where we were and where we are going- Uma Mahadevan • Infusions of IBD medications during a viral pandemic: who comes in, who stays home, how do we keep our staff safe — Iris Dotan • Which IBD pts need to be scoped? deciding who gets scoped now, who can wait, and how to return to normal — Siew Ng • Clinical trials of IBD medications — global guidance during COVID — Walter Reinisch • Can the COVID pandemic serve as a platform for research?- Dermot McGovern
JCC online supplement – COVID-19 special • Jointly supported by IOIBD and ECCO • 7-8 papers including introduction (±56 pages) • Online-only • All articles free to view
Recommend
More recommend
